PHILADELPHIA, March 22, 2012 /PRNewswire/ --
Elsevier and ExitCare work together to help customers achieve meaningful usethrough a certified EHR Module
Elsevier, the leading provider of scientific, technical and medical information products and services, today announced an expanded collaboration with ExitCare, LLC, an enterprise-wide solution for patient education. ExitCare's content already provides Elsevier customers with access to an expansive library of patient education information available in multiple languages, including the recent addition of ExitCare's patient education content within Elsevier's Clinical Pharmacology. Elsevier will also offer its customers a path to license the ExitCare software solution, which is the gateway to achieving Meaningful Use.
"We are excited to expand our relationship with Elsevier. Our content and technology products complement each other to address customers' needs such as Meaningful Use, care transitions, improving workflow, patient empowerment and more," said Roger Jacobi, President of ExitCare.
Named by independent research studies as the most complete and dependable drug compendia on the market today, Clinical Pharmacology provides comprehensive and current drug information through an easy-to-use interface, designed to find answers quickly at the point of care. Mosby's Nursing Consult leverages content from leading nursing resources to help nursing professionals find answers to their clinical questions, bringing evidence-based, best practices to the point of care.
"At Elsevier, we are committed to helping our customers improve clinical outcomes and meet meaningful use requirements when it comes to patient education," said Jay Katzen, Managing Director of Elsevier Clinical Decision Support. "Our expanded collaboration with ExitCare will support our customers both in meeting meaningful use requirements and providing consistent patient education resources to clinical staff."
About ExitCare
Founded in 1996, ExitCare, LLC is the most trusted, integrated, enterprise-wide solution for patient education and currently serves more than 1,500 healthcare facilities across the United States. With development of over 4,000 healthcare topics organized by relevant diagnosis and sourced with medication information, this system is intuitively designed and authored for all care settings, multiple languages and various health literacy levels to maximize workflow efficiency and increase patient comprehension.
About Elsevier Clinical Decision Support
Elsevier Clinical Decision Support (http://www.clinicaldecisionsupport.com), a division of Elsevier, the global leader in medical and health information, provides world class information and point-of-care technology solutions that optimize decisions and actions to improve the overall quality, safety and cost-effectiveness of care. The business delivers on this promise through actionable clinical content, care planning and documentation, drug reference and decision support, learning and performance management, and data mining and outcomes analytics solutions for provider, pharmacy and payer organizations.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Tom Reller
Vice President, Global Corporate Relations, Elsevier
+1-215-239-3508
t.reller@elsevier.com
Share this article